James Gulley - The Road to Bethesda: Search for a Cure
2017
- 14Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage14
- Abstract Views14
Article Description
Dr. James Gulley (1987) got his start at SAU then trained at LLU, Emory and the NCI to become and internationally recognized cancer immunotherapy physician scientist. He will share some of his experiences with early successes, failure and how he learned from them. His clinical trials have led to approval of Avelumab (a cancer immunotherapy agent) and another clinical trial could lead to approval soon for a second immunotherapy. Dr. Gulley will explain how our incredibly versatile immune system works to fight cancer and will offer science bases advice on how to strengthen the immune system, which could prevent cancer or decrease cancer recurrence.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know